Tag Archive for: Preclinical Development

Doris Cully, PhD, Joins Cardioxyl as Vice President, Preclinical Development

Former Director, Early Development and Discovery Sciences at Merck

Life Science Partner recruited, Doris Cully, PhD an innovative drug discovery research leader, to become Vice President, Preclinical Development at Cardioxyl Pharmaceuticals.

Developing congestive heart failure therapies, Cardioxyl produces the most advanced technology in the development of proprietary nitroxyl donors for the treatment of acute decompensated heart failure (ADHF).

Cully has an extensive background in biochemistry, cell and molecular biology, and translational biomarkers. Prior to accepting the position at Cardioxyl, Cully was the Director, Early Development and Discovery Sciences at Merck where she specialized in Cardiovascular Diseases such as hypertension, acute-decompensated heart failure, and hypertension-associated kidney disease.

In her new role at Cardioxyl, Cully will report to the Chief Scientific Officer and lead a team for the first oral HNO program, including indications for post-acute congestive heart failure and chronic heart failure.

“Cully is a savvy, hands-on scientist who has considerable experience in developing drugs from target to IND,” said Tom Callaway, MD, President of Life Science Partner.  “She can call the tough shots – including doing the critical experiments that results that illuminate critical decision points.”

After being awarded her Bachelor of Science Degree from The State University of New York at Stony Brook, Cully earned her PhD in Biomedical Sciences

/0 Comments/by

Randy Jones joins Windy Hill Medical as Vice President, Preclinical Development

Life Science Partner recruits former Vice President of Biology Services of Ricerca Biosciences

Life Science Partner announces the recruitment of Randy Jones, PhD, an experienced pharmaceutical development executive, to Windy Hill Medical to become Vice President, Preclinical Development. 

Windy Hill Medical is a California-based medical device and pharmaceutical company focused on the development of products to reduce the risk of developing breast cancer in patients deemed to be at high risk.

In Jones’ previous role at Ricerca, a preclinical chemistry and biology services company, he was responsible for the operational and profit and loss responsibility for all areas of the Biology Division as well as new business development and the integration of IND/NDA programs in biology and chemistry.  Previously, Jones served as the Director of Toxicology at the Arkansas Division of Charles River Laboratories.

“Jones is an experienced and effective general manager, unflappable in style, with a broad understanding of the pharmaceutical industry and how to build successful teams,” noted Tom Callaway, MD, founder and president of Life Science Partner.  “With his experience in medical devices as well as biopharmaceutical services, he will serve Windy Hill well in its mission to bring lasting improvements for high risk patients.”

In his role as Vice President of  Preclinical Development, Jones will have responsibility for overseeing the continued pharmaceutical development of Windy Hill Medical’s expanding portfolio of compounds under development for the localized therapy of breast cancer.  He will provide commercialization strategy and regulatory oversight to the Windy Hill team.

Jones earned his D.V.M at Iowa State University and his PhD in Pharmacology and Toxicology from the University of Georgia in Athens.

/0 Comments/by

Angiotech Pharmaceuticals Recruits Andrew Penman to Become Vice President, Preclinical Development

Life Science Partner recruits global leader in preclinical development to help accelerate product creation and add pharmaceutical expertise

Life Science Partner announces the recruitment of Andrew Penman, PhD, formerly president, preclinical development at Aptuit (a spin-out of Quintiles Transnational) to lead Angiotech Pharmaceuticals newly formed division of preclinical development. 

Angiotech is the world leader in the emerging field of drug-eluting medical devices and biomaterials.    With an accelerated program to integrate pharmaceutical and biologically active materials to improve its products, Penman will lead the preclinical development team to capitalize upon Angiotech’s considerable intellectual property portfolio to create breakthrough products.

A well-respected manager of preclinical development, Penman was responsible  for a global team of 350 people worldwide and service revenues of $55m generated through contract preclinical services in the Kansas City and UK locations.  The Company was formed by the spin-out of the preclinical group of Quintiles, a company in which he led the DMPK and Bioanalysis group.

“Andy is an excellent manager and preclinical scientist,” noted Cindi Roberts, vice  president of Life Science Partner.  “His experience in the contract-services business of preclinical drug development has honed his business and organizational skills.”

Penman joined Quintiles upon the acquisition of Pharmacia by Pfizer.  Within the pharmaceutical industry, he was director, drug metabolism and biodisposition at the Pfizer Skokie site.  He honed his skills in early drug development as President of  Cephac Europe, a 100-scientist bioanalytic division of Aster-Cephac.  His recruitment to Quintiles in 2003 was a return to the company he joined in 1995 in its Scotland-based bioanalysis group.

Penman earned his B.Sc. in Chemistry at Heriot-Watt University in Edinburgh and his Ph.D. at University of Kent in Canterbury.

/0 Comments/by